Think­ing big, Bay­er’s Ax­el Bou­chon tack­les stem cell field with $225M start­up part­nered with Ver­sant

Bay­er’s Ax­el Bou­chon has struck again.

Less than four months since the Bay­er ex­ec struck a deal with CRISPR Ther­a­peu­tics to launch a gene edit­ing JV named Case­bia, he’s back with a new col­lab­o­ra­tion, this time fo­cused on stem cells.

This time Bay­er and Bou­chon are team­ing up with Ver­sant Ven­tures to fi­nance a new com­pa­ny called Blue­Rock, hand­ing over $225 mil­lion in fi­nanc­ing to pur­sue new re­gen­er­a­tive med­i­cines for heart dis­ease and Parkin­son’s, ac­cord­ing to the Wall Street Jour­nal, which was hand­ed the ex­clu­sive ahead of a for­mal an­nounce­ment ear­ly next week.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.